Pan-cancer Assay-ready Organoid Drug Screening With Robust, Reproducible, and Clinically-relevant Output
The pharmaceutical industry traditionally used 2D cancer cell lines and 3D spheroids for testing drugs in the lab. However, these models often don't accurately predict how drugs would perform in clinical trials. To improve this, new models like patient-derived organoids (PDOs) have emerged. These PDOs better mimic actual tumors, allowing for the creation of extensive biobanks covering various cancer types and genetic profiles.
In this episode of Teach me in 10 we are joined by Dr. Marrit Putker, Director In Vitro & R&D at CrownBioscience. Together we explore CrownBioscience’s robust drug screening platform and new assay-ready organoid platform. These advancements enable quicker, high-throughput screening of drugs and extensive panel tests, offering faster results for drug screening.
Further Resources:
